{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:02:08Z","timestamp":1795035728971,"version":"4.10.2"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Purpose: Scarce information is available on the brain penetration of temozolomide (TMZ), although this novel methylating agent is mainly used for the treatment of malignant brain tumors. The purpose was to assess TMZ pharmacokinetics in plasma and cerebrospinal fluid (CSF) along with its inter-individual variability, to characterize covariates and to explore relationships between systemic or cerebral drug exposure and clinical outcomes.<\/jats:p><jats:p>Experimental Design: TMZ levels were measured by high-performance liquid chromatography in plasma and CSF samples from 35 patients with newly diagnosed or recurrent malignant gliomas. The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software. Drug exposure, defined by the area under the concentration-time curve (AUC) in plasma and CSF, was estimated for each patient and correlated with toxicity, survival, and progression-free survival.<\/jats:p><jats:p>Results: A three-compartment model with first-order absorption and transfer rates between plasma and CSF described the data appropriately. Oral clearance was 10 liter\/h; volume of distribution (VD), 30.3 liters; absorption constant rate, 5.8 h\u22121; elimination half-time, 2.1 h; transfer rate from plasma to CSF (Kplasma\u2192CSF), 7.2 \u00d7 10\u22124h\u22121 and the backwards rate, 0.76 h\u22121. Body surface area significantly influenced both clearance and VD, and clearance was sex dependent. The AUCCSF corresponded to 20% of the AUCplasma. A trend toward an increased Kplasma\u2192CSF of 15% was observed in case of concomitant radiochemotherapy. No significant correlations between AUC in plasma or CSF and toxicity, survival, or progression-free survival were apparent after deduction of dose-effect.<\/jats:p><jats:p>Conclusions: This is the first human pharmacokinetic study on TMZ to quantify CSF penetration. The AUCCSF\/AUCplasma ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-03-0807","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T23:56:19Z","timestamp":1127346979000},"page":"3728-3736","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":473,"title":["Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients"],"prefix":"10.1158","volume":"10","author":[{"given":"Sandrine","family":"Ostermann","sequence":"first","affiliation":[{"name":"1Multidisciplinary Oncology Center,"},{"name":"2Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[{"name":"2Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"2Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[{"name":"1Multidisciplinary Oncology Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdy","family":"Lejeune","sequence":"additional","affiliation":[{"name":"1Multidisciplinary Oncology Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[{"name":"2Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"1Multidisciplinary Oncology Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2004,6,1]]},"reference":[{"key":"2022061103310090400_B1","doi-asserted-by":"crossref","unstructured":"DeAngelis LM. Medical Progress: Brain Tumors. N Engl J Med, 344:\u2008114-23, \u20082001.","DOI":"10.1056\/NEJM200101113440207"},{"key":"2022061103310090400_B2","doi-asserted-by":"crossref","unstructured":"Kleihues P, Cavene WK. World Health Organization of tumors of the nervous system. Lyon: IARC\/WHO, 2000.","DOI":"10.1002\/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F"},{"key":"2022061103310090400_B3","doi-asserted-by":"crossref","unstructured":"Walker MD, Alexander E, Jr, Hunt WE, et al Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49:\u2008333-43, \u20081978.","DOI":"10.3171\/jns.1978.49.3.0333"},{"key":"2022061103310090400_B4","doi-asserted-by":"crossref","unstructured":"Kristiansen K, Hagen S, Kollevold T, et al Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47:\u2008649-52, \u20081981.","DOI":"10.1002\/1097-0142(19810215)47:4<649::AID-CNCR2820470405>3.0.CO;2-W"},{"key":"2022061103310090400_B5","doi-asserted-by":"crossref","unstructured":"Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer, 82:\u20081371-80, \u20082000.","DOI":"10.1054\/bjoc.1999.1075"},{"key":"2022061103310090400_B6","unstructured":"Prados M. . Brain Cancer, BC Decker Inc. Hamilton, London \u20082002."},{"key":"2022061103310090400_B7","unstructured":"Stevens MF, Hickman JA, Langdon SP, et al Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res, 47:\u20085846-52, \u20081987."},{"key":"2022061103310090400_B8","doi-asserted-by":"crossref","unstructured":"Newlands ES, Blackledge GRP, Slack JA, et al Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). Br J Cancer, 65:\u2008287-91, \u20081992.","DOI":"10.1038\/bjc.1992.57"},{"key":"2022061103310090400_B9","doi-asserted-by":"crossref","unstructured":"Brada M, Judson I, Beale P, et al Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer, 81:\u20081022-30, \u20081999.","DOI":"10.1038\/sj.bjc.6690802"},{"key":"2022061103310090400_B10","doi-asserted-by":"crossref","unstructured":"Yung WK, Albright RE, Olson J, et al A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83:\u2008588-93, \u20082000.","DOI":"10.1054\/bjoc.2000.1316"},{"key":"2022061103310090400_B11","doi-asserted-by":"crossref","unstructured":"Yung WK, Prados MD, Yaya-Tur R, et al Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol, 17:\u20082762-71, \u20081999.","DOI":"10.1200\/JCO.1999.17.9.2762"},{"key":"2022061103310090400_B12","doi-asserted-by":"crossref","unstructured":"Brada M, Hoang-Xuang K, Rampling R, et al Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol, 12:\u2008259-66, \u20082001.","DOI":"10.1023\/A:1008382516636"},{"key":"2022061103310090400_B13","doi-asserted-by":"crossref","unstructured":"Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev, 23:\u200835-61, \u20081997.","DOI":"10.1016\/S0305-7372(97)90019-0"},{"key":"2022061103310090400_B14","doi-asserted-by":"crossref","unstructured":"Tsang LL, Farmer PB, Gescher A, Slack JA. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol, 26:\u2008429-36, \u20081990.","DOI":"10.1007\/BF02994094"},{"key":"2022061103310090400_B15","unstructured":"Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res, 44:\u20081772-5, \u20081984."},{"key":"2022061103310090400_B16","doi-asserted-by":"crossref","unstructured":"Marzolini C, Decosterd LA, Shen F, et al Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol, 42:\u2008433-40, \u20081998.","DOI":"10.1007\/s002800050842"},{"key":"2022061103310090400_B17","doi-asserted-by":"crossref","unstructured":"Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol, 61:\u2008203-7, \u20082003.","DOI":"10.1023\/A:1022592913323"},{"key":"2022061103310090400_B18","doi-asserted-by":"crossref","unstructured":"Stupp R, Dietrich P, Ostermann Kraljevic S, et al Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20:\u20081375-82, \u20082002.","DOI":"10.1200\/JCO.2002.20.5.1375"},{"key":"2022061103310090400_B19","unstructured":"Stupp R, Maeder P, Pica A, et al Improved outcome with chemotherapy with temozolomide for recurrent glioblastoma and anaplastic astrocytoma [abstract]. J Neurooncol, 39:\u2008151\u20081998."},{"key":"2022061103310090400_B20","doi-asserted-by":"crossref","unstructured":"Shen F, Decosterd LA, Gander M, Leyvraz S, Biollaz J, Lejeune F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl, 667:\u2008291-300, \u20081995.","DOI":"10.1016\/0378-4347(95)00040-P"},{"key":"2022061103310090400_B21","doi-asserted-by":"crossref","unstructured":"Shah VP, Midha KK, Findlay JW, et al Bioanalytical method validation\u2013a revisit with a decade of progress. Pharm Res, 17:\u20081551-7, \u20082000.","DOI":"10.1023\/A:1007669411738"},{"key":"2022061103310090400_B22","unstructured":"Beal SL, Sheiner LB. . NONMEM user\u2019s guides, NONMEM Project Group San Francisco \u20081992."},{"key":"2022061103310090400_B23","doi-asserted-by":"crossref","unstructured":"Gumerlock MK, Neuwelt EA. Principles of chemotherapy in brain neoplasm Jellinger K eds. . Therapy of malignant brain tumors, Springer-Verlag Vienna \u20081987.","DOI":"10.1007\/978-3-7091-8876-7_6"},{"key":"2022061103310090400_B24","doi-asserted-by":"crossref","unstructured":"de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet, 41:\u2008691-703, \u20082002.","DOI":"10.2165\/00003088-200241100-00001"},{"key":"2022061103310090400_B25","doi-asserted-by":"crossref","unstructured":"DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight is know. Arch Intern Med, 17:\u2008863-71, \u20081916.","DOI":"10.1001\/archinte.1916.00080130010002"},{"key":"2022061103310090400_B26","doi-asserted-by":"crossref","unstructured":"Samara E, Granneman R. Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet, 32:\u2008294-312, \u20081997.","DOI":"10.2165\/00003088-199732040-00003"},{"key":"2022061103310090400_B27","doi-asserted-by":"crossref","unstructured":"Zhou H, Choi L, Lau H, et al Population pharmacokinetics\/toxicodynamics (PK\/TD) relationship of SAM486A in phase I studies in patients with advanced cancers. J Clin Pharmacol, 40:\u2008275-83, \u20082000.","DOI":"10.1177\/00912700022008946"},{"key":"2022061103310090400_B28","doi-asserted-by":"crossref","unstructured":"Toffoli G, Corona G, Sorio R, et al Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol, 52:\u2008511-9, \u20082001.","DOI":"10.1046\/j.0306-5251.2001.01468.x"},{"key":"2022061103310090400_B29","unstructured":"Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin T, Decostered L. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration (abstract 232). Proc Am Soc Clin Oncol, 20:\u200859a\u20082001."},{"key":"2022061103310090400_B30","doi-asserted-by":"crossref","unstructured":"Nau R, Zysk G, Thiel A, Prange HW. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Eur J Clin Pharmacol, 45:\u2008469-75, \u20081993.","DOI":"10.1007\/BF00315520"},{"key":"2022061103310090400_B31","doi-asserted-by":"crossref","unstructured":"Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8:\u20081277-80, \u20081990.","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"2022061103310090400_B32","doi-asserted-by":"crossref","unstructured":"Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology, 38:\u2008724-6, \u20081988.","DOI":"10.1212\/WNL.38.5.724"},{"key":"2022061103310090400_B33","doi-asserted-by":"crossref","unstructured":"Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA, 79:\u20084420-3, \u20081982.","DOI":"10.1073\/pnas.79.14.4420"},{"key":"2022061103310090400_B34","doi-asserted-by":"crossref","unstructured":"Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol, 20:\u2008121-39, \u20081994.","DOI":"10.1007\/BF01052723"},{"key":"2022061103310090400_B35","doi-asserted-by":"crossref","unstructured":"Bruno R, Hille D, Riva A, et al Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol, 16:\u2008187-96, \u20081998.","DOI":"10.1200\/JCO.1998.16.1.187"},{"key":"2022061103310090400_B36","doi-asserted-by":"crossref","unstructured":"Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol, 20:\u20083293-301, \u20082002.","DOI":"10.1200\/JCO.2002.11.073"},{"key":"2022061103310090400_B37","doi-asserted-by":"crossref","unstructured":"Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol, 18:\u20082459-67, \u20082000.","DOI":"10.1200\/JCO.2000.18.12.2459"},{"key":"2022061103310090400_B38","doi-asserted-by":"crossref","unstructured":"Kerbusch T, Huitema AD, Ouwerkerk J, et al Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br J Clin Pharmacol, 49:\u2008555-61, \u20082000.","DOI":"10.1046\/j.1365-2125.2000.00217.x"},{"key":"2022061103310090400_B39","doi-asserted-by":"crossref","unstructured":"Batey MA, Wright JG, Azzabi A, et al Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer, 38:\u20081081-9, \u20082002.","DOI":"10.1016\/S0959-8049(02)00024-2"},{"key":"2022061103310090400_B40","doi-asserted-by":"crossref","unstructured":"Delord JP, Umlil A, Guimbaud R, et al Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol, 51:\u2008127-31, \u20082003.","DOI":"10.1007\/s00280-002-0550-3"},{"key":"2022061103310090400_B41","doi-asserted-by":"crossref","unstructured":"Gieschke R, Burger HU, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol, 55:\u2008252-63, \u20082003.","DOI":"10.1046\/j.1365-2125.2003.01765.x"},{"key":"2022061103310090400_B42","doi-asserted-by":"crossref","unstructured":"Van Kesteren C, Mathot RA, Raymond E, et al Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol, 20:\u20084065-73, \u20082002.","DOI":"10.1200\/JCO.2002.01.005"},{"key":"2022061103310090400_B43","unstructured":"Jen JF, Cutler DL, Pai SM, et al Population pharmacokinetics of temozolomide in cancer patients. Pharm Res, 17:\u20081284-9, \u20082000."},{"key":"2022061103310090400_B44","doi-asserted-by":"crossref","unstructured":"Blaney SM, Takimoto C, Murry DJ, et al Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol, 41:\u2008464-8, \u20081998.","DOI":"10.1007\/s002800050768"},{"key":"2022061103310090400_B45","unstructured":"Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res, 53:\u2008725-7, \u20081993."},{"key":"2022061103310090400_B46","doi-asserted-by":"crossref","unstructured":"Friedman HS, Petros WP, Friedman AH, et al : Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol, 17:\u20081516-25, \u20081999.","DOI":"10.1200\/JCO.1999.17.5.1516"},{"key":"2022061103310090400_B47","doi-asserted-by":"crossref","unstructured":"Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol, 20:\u20082388-99, \u20082002.","DOI":"10.1200\/JCO.2002.06.110"},{"key":"2022061103310090400_B48","doi-asserted-by":"crossref","unstructured":"Tolcher AW, Gerson SL, Denis L, et al Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer, 88:\u20081004-11, \u20082003.","DOI":"10.1038\/sj.bjc.6600827"},{"key":"2022061103310090400_B49","doi-asserted-by":"crossref","unstructured":"d\u2019Avella D, Cicciarello R, Angileri FF, Lucerna S, La Torre D, Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl (Wien), 71:\u2008282-4, \u20081998.","DOI":"10.1007\/978-3-7091-6475-4_82"},{"key":"2022061103310090400_B50","doi-asserted-by":"crossref","unstructured":"Adair JC, Baldwin N, Kornfeld M, Rosenberg GA. Radiation-induced blood-brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase. J Neurooncol, 44:\u2008283-9, \u20081999.","DOI":"10.1023\/A:1006337912345"},{"key":"2022061103310090400_B51","doi-asserted-by":"crossref","unstructured":"Qin D, Ou G, Mo H, et al Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys, 51:\u2008959-62, \u20082001.","DOI":"10.1016\/S0360-3016(01)01735-7"},{"key":"2022061103310090400_B52","doi-asserted-by":"crossref","unstructured":"Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol, 19:\u20081111-7, \u20082001.","DOI":"10.1200\/JCO.2001.19.4.1111"},{"key":"2022061103310090400_B53","doi-asserted-by":"crossref","unstructured":"Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol, 2:\u200845-59, \u20082000.","DOI":"10.1215\/15228517-2-1-45"},{"key":"2022061103310090400_B54","doi-asserted-by":"crossref","unstructured":"Baker SD, Verweij J, Rowinsky EK, et al Role of body surface area in dosing of investigational anticancer agents in adults, 1991\u20132001. J Natl Cancer Inst (Bethesda), 94:\u20081883-8, \u20082002.","DOI":"10.1093\/jnci\/94.24.1883"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/11\/3728\/1952230\/zdf01104003728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/11\/3728\/1952230\/zdf01104003728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T18:39:00Z","timestamp":1683225540000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/10\/11\/3728\/181826\/Plasma-and-Cerebrospinal-Fluid-Population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2004,6,1]]},"published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0807","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}